Awareness and Early Detection Remain Key Issues in Ovarian Cancer
Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.
Related Articles
Revisit Every OncLive On Air Episode From October 2024
In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC
First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.
Secretory carcinoma of the salivary gland, a rare entity: An international multi‐institutional study
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
A systematic review on performance characteristics of FNA of renal lesions: It is time for a standardized classification system
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC
The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.
Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches
John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Patient Communication is Key to Delivering Optimal PARP Inhibitor Treatment in Ovarian Cancer
Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.